Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL
Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).
30 July 2025
30 July 2025
Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.